Equity Profile

TECH

Bio-Techne Corporation

Health CareLife Sciences Tools & Services$11.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Bio-Techne Corporation operates in the health care sector, specializing in life sciences tools and services. The company provides essential products and services that support research and clinical applications, making it a key player in the growing biotechnology market.

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

0.52

Revenue

Revenue figures will help assess the company's sales performance and market demand for its products.

315M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock dropped 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Bio-Techne to report solid earnings this quarter, with a consensus EPS of $0.52 and revenue of $315 million. The market is closely watching for any signs of growth or potential challenges.

Bull Case

If Bio-Techne beats earnings expectations again, it could signal strong demand for its products and lead to positive market sentiment.

Bear Case

Conversely, any miss on earnings or revenue could raise concerns about market demand and lead to a further decline in stock price.

Key Metrics to Watch

EPS

0.52

Earnings per share is a crucial indicator of the company's profitability and financial health.

Revenue

315M

Revenue figures will help assess the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.52?

A beat could reinforce confidence in the company's growth trajectory, while a miss could raise concerns about demand.

What are the revenue expectations compared to the consensus of $315 million?

Revenue performance is critical for assessing the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Techne's ability to capitalize on emerging trends in biotechnology, particularly in areas like personalized medicine.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger underlying performance than anticipated.

The options market is pricing in a significant move, suggesting that investors expect more volatility than the consensus reflects.

Key Risk

If revenue growth exceeds $320 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Techne can sustain its growth amid competitive pressures and changing market dynamics.

Bull Confirmed If

An EPS of $0.54 or higher would confirm the bull case, indicating strong demand and profitability.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, suggesting potential issues with sales or market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests the stock could rise by around 2.89%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of about 2.11%, reflecting market disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management strategies and their impact on margins.
4Discussion of any potential acquisitions or partnerships that could enhance growth.
5Guidance on future revenue expectations and market outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

0.52

Revenue

Revenue figures will help assess the company's sales performance and market demand for its products.

315M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock dropped 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Bio-Techne beats earnings expectations again, it could signal strong demand for its products and lead to positive market sentiment.

Bear Case

Conversely, any miss on earnings or revenue could raise concerns about market demand and lead to a further decline in stock price.

Key Metrics to Watch

EPS

0.52

Earnings per share is a crucial indicator of the company's profitability and financial health.

Revenue

315M

Revenue figures will help assess the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.52?

A beat could reinforce confidence in the company's growth trajectory, while a miss could raise concerns about demand.

What are the revenue expectations compared to the consensus of $315 million?

Revenue performance is critical for assessing the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Techne's ability to capitalize on emerging trends in biotechnology, particularly in areas like personalized medicine.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger underlying performance than anticipated.

The options market is pricing in a significant move, suggesting that investors expect more volatility than the consensus reflects.

Key Risk

If revenue growth exceeds $320 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Techne can sustain its growth amid competitive pressures and changing market dynamics.

Bull Confirmed If

An EPS of $0.54 or higher would confirm the bull case, indicating strong demand and profitability.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, suggesting potential issues with sales or market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests the stock could rise by around 2.89%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of about 2.11%, reflecting market disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management strategies and their impact on margins.
4Discussion of any potential acquisitions or partnerships that could enhance growth.
5Guidance on future revenue expectations and market outlook.